Home » Topics » Regulatory » EMA

EMA
RSS

Activartis gives update on its anticancer immune therapy for glioma

March 14, 2013

Roche obtains E.U. approval for Perjeta

March 6, 2013

EMA grants orphan drug status to Prothena's candidate for amyloid light-chain amyloidosis

March 5, 2013

EMA recommends approval of Sanofi Pasteur pediatric vaccine

Feb. 27, 2013

EMA confirms decision on VIVUS' MAA for obesity treatment

Feb. 25, 2013

EMA grants orphan designation to BHR Pharma's investigational agent for traumatic brain injury

Feb. 14, 2013

Prolor Biotech's hGH-CTP receives orphan drug designation in Europe

Feb. 14, 2013

Pediatric indication of Ixiaro approved in Europe

Feb. 12, 2013

EMA committee begins safety review of Diane-35 and generics

Feb. 11, 2013

EMA grants accelerated assessment to trametinib application

Feb. 8, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...